Egetis Therapeutics ABPDPHF 24 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,205 Biotechnology companies, Egetis Therapeutics AB ranks worse than 82987.47% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Egetis Therapeutics AB's annualized net income for the quarter that ended in Mar. 2026 was $-40.57 Mil. Egetis Therapeutics AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-8.01 Mil. Therefore, Egetis Therapeutics AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Egetis Therapeutics AB's Return-on-Tangible-Equity or its related term are showing as below:
PDPHF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.59 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Egetis Therapeutics AB (OTCPK:PDPHF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Egetis Therapeutics AB Return-on-Tangible-Equity Related Terms
Egetis Therapeutics AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Egetis Therapeutics AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB Return-on-Tangible-Equity Chart
PDPHF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Egetis Therapeutics AB (PDPHF) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Egetis Therapeutics AB and its competitors. According to the industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 1205 companies in the Biotechnology industry.
Is Egetis Therapeutics AB's Return-on-Tangible-Equity too high?
Egetis Therapeutics AB's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Egetis Therapeutics AB ranks #999999 out of 1205 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 1205 companies for Return-on-Tangible-Equity. This places Egetis Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued.
The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64.
GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.
Key valuation signals for PDPHF:
Return-on-Tangible-Equity: 0.00%
GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score
Get the complete analysis for PDPHF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
